Intravesical idarubicin: a dose-finding study

Cancer Chemotherapy and Pharmacology
F BoccardoA Curotto

Abstract

A total of 12 patients with completely resected, recurrent papillary tumors of the bladder were entered into a dose-finding study using intravesical idarubicin, a new anthracycline agent that has been shown in vitro to be more active than doxorubicin or daunorubicin, its parental compound. Patients were scheduled to receive eight weekly instillations with the following dose levels: 6.5, 12.5, and 20 mg, all of them diluted in 50 ml saline. Each dose level was initially studied in 3 patients. Dose escalation in the individual patients was not allowed so as to avoid undue toxicity and to evaluate the cumulative toxicity induced by each dose level. Overall, 4 patients were withdrawn due to severe local toxicity (chemocystitis) after a median of 2 instillations (range 1-3) and 3 more patients refused to continue treatment due to mild to moderate toxicity after a median of 4 instillations (range 2-4). Both the patients treated with 20 mg idarubicin and 2 of the 6 patients treated with 12.5 mg were withdrawn due to local toxicity. In contrast, no systemic toxicity was encountered at any dose level. We conclude that doses ranging from 6.5 to 12.5 mg and concentrations varying between 0.125 and 0.250 mg/ml are more appropriate for phas...Continue Reading

Citations

Aug 26, 1998·Proceedings of the National Academy of Sciences of the United States of America·N D Lawson, N Berliner
Oct 14, 1998·Japanese Journal of Clinical Oncology·I SekineN Saijo
Aug 6, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Munazza Tamkeen FatimaGhulam Md Ashraf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Related Papers

Biulleten' eksperimental'noĭ biologii i meditsiny
Iu V PashinT I Bentkhen
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
C A VerburghL A van Es
© 2021 Meta ULC. All rights reserved